Amgen Boulder Inc.
Records under this name other than patents Amgen Boulder Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,858,409 | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors Formerly held Term ended Term ended Feb 22, 2022 · USPTO record | Term ended | Term ended Feb 22, 2022 | USPTO record |
| US 6,541,620 | Nucleic acids encoding TNF inhibitor and method of production Formerly held Term ended Ended no later than Apr 1, 2020 · USPTO record | Term ended | Ended no later than Apr 1, 2020 | USPTO record |
| US 6,440,693 | TNF receptors, TNF binding proteins and DNAS coding for them Term ended Ended no later than Aug 27, 2019 · USPTO record | Term ended | Ended no later than Aug 27, 2019 | USPTO record |
| US 6,417,158 | Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF Term ended Term ended Jul 9, 2019 · USPTO record | Term ended | Term ended Jul 9, 2019 | USPTO record |
| US 6,294,352 | TNF receptors, TNF binding proteins and DNAs coding for them Term ended Term ended Sep 25, 2018 · USPTO record | Term ended | Term ended Sep 25, 2018 | USPTO record |
| US 6,271,346 | TNF Receptors, TNF binding proteins and DNAs coding for them Term ended Term ended Aug 7, 2018 · USPTO record | Term ended | Term ended Aug 7, 2018 | USPTO record |
| US 6,221,675 | TNF receptors, TNF binding proteins and DNAs coding for them Formerly held Term ended Term ended Apr 24, 2018 · USPTO record | Term ended | Term ended Apr 24, 2018 | USPTO record |
| US 6,143,866 | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same Formerly held Term ended Term ended Nov 7, 2017 · USPTO record | Term ended | Term ended Nov 7, 2017 | USPTO record |
| US 6,869,925 | Inhibition of retrovirus infection Formerly held Lapsed on the fee record Ended Mar 22, 2017 · USPTO record | Lapsed on the fee record | Ended Mar 22, 2017 | USPTO record |
| US 6,096,728 | Composition and method for treating inflammatory diseases Formerly held Term ended Term ended Feb 7, 2017 · USPTO record | Term ended | Term ended Feb 7, 2017 | USPTO record |